Peter Anastasiou to Lead Harmony Biosciences Starting 2027

Anastasiou’s transition into the top leadership role is part of a planned succession strategy. To ensure continuity during the handover, Dayno will remain with the organization through 2027, serving as a non-executive adviser focused on long-term growth objectives. The change in executive management comes as the company maintains a stable financial outlook for its primary asset. Harmony confirmed its full-year 2026 revenue guidance for Wakix, the prescription treatment for narcolepsy-related cataplexy and excessive daytime sleepiness, at $1 billion to $1.04 billion.